vida: extract claims from 2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis

- Source: inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md

@@ -24,3 +24,10 @@ Converging evidence from multiple 2025-2026 trials reveals a clear anatomical pa
 **Source:** Exenatide-PD3 Phase 3 RCT, Lancet February 2025
 
 Exenatide Phase 3 trial (n=194, 96 weeks) failed all endpoints in Parkinson's disease: no motor benefit, no non-motor benefit, and critically, DaT-SPECT imaging showed zero dopaminergic neuroprotection signal. CSF analysis revealed insufficient drug penetration to substantia nigra despite exenatide crossing the BBB in other brain regions. This confirms the circuit-specificity principle: GLP-1 agonists succeed in reward/dopamine circuits (SUD, MDD) but fail in neurodegenerative contexts where the mechanism is protein aggregation (α-synuclein) rather than reward dysregulation.
+
+
+## Supporting Evidence
+
+**Source:** NBC News synthesis April 2026, Session 22 Science 2025
+
+GLP-1 receptor expression in ventral tegmental area (VTA) and nucleus accumbens (NAc) enables reward circuit modulation across multiple substance classes. Session 22 Science 2025 paper confirmed VTA dopamine circuit adaptation during repeat GLP-1 treatment (mice recover hedonic eating), suggesting efficacy may fade with long-term use for some reward circuits. This shared VTA dopamine mechanism explains why GLP-1 effects generalize across AUD, OUD, nicotine, and food reward — all operate through the same mesolimbic pathway.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -171,3 +171,10 @@ Contradictory animal evidence on dopamine mechanism: one lab found 'chronically
 **Source:** JAMA Psychiatry RCT + PMC systematic review
 
 Semaglutide + CBT for AUD achieved 41.1% reduction in heavy drinking days with NNT 4.3 (vs. 7+ for approved AUD medications) in double-blind RCT (N=108). Mechanistic hypothesis: GLP-1 reduces reward salience through mesolimbic dopamine modulation, beneficial for addiction/cravings. However, this same mechanism may reduce hedonic response broadly, potentially explaining the 195% MDD risk signal in observational cohort data.
+
+
+## Extending Evidence
+
+**Source:** NBC News/Pharmacy Times synthesis April 2026, Session 22 Science 2025 VTA dopamine circuit paper
+
+GLP-1 receptor agonists show evidence across multiple substance use disorders beyond AUD: (1) Opioid Use Disorder: liraglutide produced ~40% reduction in opioid craving in small RCT; semaglutide significantly reduced opioid overdose risk in 1-year follow-up for T2D+OUD patients (real-world data). (2) Nicotine: exenatide + NRT increased 7-day abstinence vs placebo at week 6, though long-term findings mixed; SEMALCO trial showed reduced cigarettes/day as secondary endpoint in AUD+smoking subgroup. (3) Cocaine/stimulants: liraglutide reduces operant methamphetamine intake in rats (preclinical only). Population-level evidence: among people with pre-existing SUD on GLP-1s, fewer ER visits, hospitalizations, and deaths across substance categories (observational data). As of April 2026: 33 clinical trials for SUD (15 AUD, 9 nicotine, 4 OUD, 4 cocaine). Evidence strength hierarchy: AUD > OUD > nicotine > cocaine.

domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md

@@ -12,7 +12,7 @@ scope: causal
 sourcer: NIH / JAMA Psychiatry
 supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
 challenges: ["the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
-related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients"]
 ---
 
 # GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
@@ -39,3 +39,10 @@ Meta-analysis demonstrates effect extends beyond comorbid obesity population to
 **Source:** VigiBase study, Clinical Nutrition 2025
 
 VigiBase pharmacovigilance analysis shows eating disorder signals with aROR 4.17-6.80 across all three GLP-1 RAs (semaglutide, dulaglutide, liraglutide), suggesting GLP-1's appetite suppression mechanism may precipitate eating disorder pathology in vulnerable individuals. This is a class effect, not drug-specific, indicating the reward pathway modulation that benefits AUD may create eating disorder risk in susceptible populations.
+
+
+## Extending Evidence
+
+**Source:** NBC News/Pharmacy Times April 2026
+
+Critical limitation applies across all SUD evidence: all human data comes from patients with comorbid metabolic disease (T2D or obesity). Whether GLP-1s work for SUD without metabolic comorbidity is unknown and largely unstudied. This constraint affects not just AUD but the entire SUD evidence base — OUD, nicotine, and cocaine trials all recruit from metabolically compromised populations.

inbox/archive/health/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md

@@ -7,10 +7,13 @@ date: 2026-04-28
 domain: health
 secondary_domains: []
 format: news-analysis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: medium
 tags: [GLP-1, addiction, opioid-use-disorder, nicotine, cocaine, substance-use-disorder, VTA-dopamine, reward-mechanism]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content